Shawn Davies, Amanda Howarth, John Schneider and Andy Briggs of AHE are presenting their poster at ERA-EDTA: ‘A cost-offset analysis of the roxadustat dialysis-dependent global phase 3 programme: a Canadian healthcare perspective.
Abstract
Background and Aims
Chronic kidney disease (CKD) is a costly public health issue, which affects 13.4% of the population globally. Anaemia is a common complication in patients with CKD resulting in reduced health-related quality of life and high healthcare costs. The objective of this analysis was to estimate the direct medical care cost offsets of the investigational agent roxadustat for the treatment of anaemia in patients with dialysis-dependent (DD) CKD from a Canadian healthcare perspective.